The current earnings forecast score of Immunocore Holdings PLC is 8.13, ranking 51 out of 155 in the Pharmaceuticals industry. The average price target is 70.00, with a high of 100.00 and a low of 36.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
66.846
Target Price
+97.71%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Immunocore Holdings PLC
IMCR
15
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Immunocore Holdings PLC's expected revenue for the next quarter?
Immunocore Holdings PLC's expected revenue is 110.23M.
What is Immunocore Holdings PLC's price target?
Analysts forecast that Immunocore Holdings PLC's price target is USD 70.00, with the highest forecast at USD 100.00 and the lowest forecast at USD 36.00.
How have Immunocore Holdings PLCIMCR's recent earnings per share performed?
The market expectation was USD 0.26, while Immunocore Holdings PLCIMCR's earnings per share (EPS) for the previous quarter was USD -0.59. EPS for the next quarter is expected at USD 0.01.
What is the analyst rating for Immunocore Holdings PLC?
Based on the ratings of Immunocore Holdings PLC's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.